^
Association details:
| Biomarker: | AR negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + cyclophosphamide (Alkylating agent) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer
Published date:
03/01/2022
Excerpt:
AR+ tumors were associated with favorable characteristics. AR+ patients had better 5-year recurrence-free survival rates and the risk of recurrence was greater for AR- than for AR+ patients. AR- status predicted the failure of adjuvant endocrine therapy with aromatase inhibitors and of adjuvant chemotherapy with docetaxel plus cyclophosphamide.
DOI:
10.2217/fon-2021-1300
